HRSA delays to July effective date of 340B drug ceiling price rule

Sep 28, 2017 - 03:03 PM

The Health Resources and Services Administration today delayed to July 1, 2018 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. “We are delaying the effective date of the Jan. 5, 2017, final rule to July 1, 2018, because the delay will provide stakeholders with additional time to come into compliance and provide time to consider the substantial questions of fact, law and policy raised by the rule,” the agency said. AHA had opposed any further delay of the rule, which has been subject to multiple delays since January. “The agency’s rulemaking on these issues began seven years ago, shortly after the passage of the ACA,” AHA Executive Vice President Tom Nickels said in comments submitted last week. “This process included an advance notice of proposed rulemaking, a notice of proposed rulemaking, a final rule and now an interim final rule. Therefore, there have been extensive opportunities for stakeholders to provide feedback and ample time for HRSA to consider such feedback.”

Related News Articles

Headline
Appeals court upholds lower court denial of AbbVie’s preliminary injunction, preserving Mississippi 340B contract pharmacy law
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Perspective
Hospital Outpatient Departments Are Different from Independent Physician Offices
Public
Every health care provider strives to deliver their patients the best possible care, but not all providers offer the same level or complexity of care. Current…
Headline
Study: MA beneficiaries’ hospital stays longer than those under Traditional Medicare
A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer…
Headline
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models 
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
Study finds less than 40% of Medicare beneficiaries with OUD receive standard care
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
AHA study finds HOPDs treat sicker patients than independent physician offices
The AHA Sept. 3 released a study conducted by KNG Health Consulting that found Medicare patients who receive care in a hospital outpatient department are more…